Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Oncolin Therapeutics signs research agreement with M.D. Anderson
July 2008
SHARING OPTIONS:

HOUSTON—Oncolin Therapeutics Inc., a publicly traded biopharmaceutical company focused on the discovery and development of novel selective anticancer therapies, last month signed a sponsored research agreement with The University of Texas M. D. Anderson Cancer Center to support work in the laboratory of world renowned cancer research scientist Dr. Waldemar Priebe. The sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors. The agreement gives Oncolin the exclusive right to license to any new patents derived from the research.






 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.